A new liver disease awareness video from Madrigal Pharmaceuticals follows a patient advocate spreading the word to take NASH seriously. (Number One Liver Fan via YouTube)

November 10, 2023 09:24 AM EST

Marketing

Madrigal builds on liver disease awareness campaigns as it awaits FDA decision on NASH drug resmetirom

Beth Snyder Bulik

Senior Editor

Madrigal Pharmaceuticals wants people with fatty liver disease to be the number one fan of their livers. Its new “patient service announcement,” shown first on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Madrigal builds on liver disease awareness campaigns as it awaits FDA decision on NASH drug resmetirom

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Madri­gal builds on liv­er dis­ease aware­ness cam­paigns as it awaits FDA de­ci­sion on NASH drug resme­tirom

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Madrigal builds on liver disease awareness campaigns as it awaits FDA decision on NASH drug resmetirom

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?